2020: An Innovation Odyssey? FDA’s Ganley Pushes For Forward-Thinking
This article was originally published in The Tan Sheet
Executive Summary
Growth in the OTC drug industry has stalled because the industry failed to think towards the future a decade ago, according to FDA OTC Drug Products Division Director Charles Ganley, MD
You may also be interested in...
Rx Firms Keeping A Close Eye On Lagging OTC Market Growth
Roche's decision to shop its OTC unit is an example of a pharmaceutical company putting increased profit margins ahead of long-term steady cash flow
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands